Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 474121 in Healthy Japanese Male Subjects (Doubleblind, Randomised, Placebo-controlled, Parallel Group Design)
Latest Information Update: 11 Mar 2024
Price :
$35 *
At a glance
- Drugs BI 474121 (Primary)
- Indications Alzheimer's disease; Schizophrenia
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 18 Nov 2021 Status changed from recruiting to completed.
- 04 Nov 2021 Planned End Date changed from 9 Nov 2021 to 11 Nov 2021.
- 04 Nov 2021 Planned primary completion date changed from 9 Nov 2021 to 11 Nov 2021.